@cdr-life.bsky.social
Dr. Matteo Morotti represented CDR-Life in a Citeline roundtable on the future of immuno-oncology, where leaders discussed how bi- and tri-specific antibodies, T-cell engagers and other next-gen modalities are reshaping the landscape.
Download! discover.pharmaignite.com/novotech-esm...
Download! discover.pharmaignite.com/novotech-esm...
Breaking Through the Checkpoint Blockade in Immuno-Oncology
discover.pharmaignite.com
December 12, 2025 at 2:51 PM
Dr. Matteo Morotti represented CDR-Life in a Citeline roundtable on the future of immuno-oncology, where leaders discussed how bi- and tri-specific antibodies, T-cell engagers and other next-gen modalities are reshaping the landscape.
Download! discover.pharmaignite.com/novotech-esm...
Download! discover.pharmaignite.com/novotech-esm...
We’re heading to #JPM2026 to share how our antibody-based M-gager® T cell engagers are opening new paths in solid tumors and autoimmune disease. With emerging first-in-human activity for CDR404 and strong pipeline momentum, we’re excited for the year ahead. Let’s meet!
December 8, 2025 at 12:24 PM
We’re heading to #JPM2026 to share how our antibody-based M-gager® T cell engagers are opening new paths in solid tumors and autoimmune disease. With emerging first-in-human activity for CDR404 and strong pipeline momentum, we’re excited for the year ahead. Let’s meet!
We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25
December 4, 2025 at 1:54 PM
We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25
For National Future Day, CDR-Life opened its labs to students eager to learn how medicines are discovered and developed. Partnering with Life Science Cares Switzerland ensures that opportunities like this reach children who might otherwise never see science up close. #Zukunftstag
November 14, 2025 at 4:43 PM
For National Future Day, CDR-Life opened its labs to students eager to learn how medicines are discovered and developed. Partnering with Life Science Cares Switzerland ensures that opportunities like this reach children who might otherwise never see science up close. #Zukunftstag
Chief Business Officer Sarah Holland joins an expert panel at the LSX Informa Investival Showcase, sharing strategies for winning in today’s shifting biopharma and medtech partnering landscape.
November 13, 2025 at 12:20 PM
Chief Business Officer Sarah Holland joins an expert panel at the LSX Informa Investival Showcase, sharing strategies for winning in today’s shifting biopharma and medtech partnering landscape.
Thrilled to expand our partnership w @boehringerglobal.bsky.social to advance CDR111, a trispecific M-gager® designed for broad B-cell depletion in autoimmune diseases. This validates the reach of our antibody fragment–based T-cell engager platform beyond oncology and retinal health. bit.ly/492ru2m
November 4, 2025 at 1:12 PM
Thrilled to expand our partnership w @boehringerglobal.bsky.social to advance CDR111, a trispecific M-gager® designed for broad B-cell depletion in autoimmune diseases. This validates the reach of our antibody fragment–based T-cell engager platform beyond oncology and retinal health. bit.ly/492ru2m
CDR-Life’s Sarah Holland joins #BIOEurope in Vienna to discuss our M-gager® platform, advancing potent, precise T cell engagers for solid tumors and autoimmune diseases.
Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!
Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!
October 28, 2025 at 4:23 PM
CDR-Life’s Sarah Holland joins #BIOEurope in Vienna to discuss our M-gager® platform, advancing potent, precise T cell engagers for solid tumors and autoimmune diseases.
Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!
Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!
Our team will be in London for #JefferiesHealthcare, sharing how our M-gager® platform is setting a new benchmark for T cell engager precision, unlocking new possibilities in both solid tumors and autoimmune diseases.
We welcome the chance to connect!
We welcome the chance to connect!
October 27, 2025 at 3:21 PM
Our team will be in London for #JefferiesHealthcare, sharing how our M-gager® platform is setting a new benchmark for T cell engager precision, unlocking new possibilities in both solid tumors and autoimmune diseases.
We welcome the chance to connect!
We welcome the chance to connect!
Early clinical data from CDR404 show all four hallmarks of T cell engager activity in patients with advanced MAGE-A4+ solid tumors, validating the potency of our M-gager® platform and its ability to reach intracellular targets once thought out of reach for antibody-based therapeutics.
bit.ly/47Cj00p
bit.ly/47Cj00p
October 23, 2025 at 5:07 PM
Early clinical data from CDR404 show all four hallmarks of T cell engager activity in patients with advanced MAGE-A4+ solid tumors, validating the potency of our M-gager® platform and its ability to reach intracellular targets once thought out of reach for antibody-based therapeutics.
bit.ly/47Cj00p
bit.ly/47Cj00p
CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting!
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE
October 13, 2025 at 4:15 PM
CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting!
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE
Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs:
• CDR404 – MAGE-A4+ solid tumors
• CDR609 – First-in-class LGR5-targeted TCE
Proud to have our CBO Sarah Holland chair the Pharma Strategy & Dealmaking Panel at the #Sachs_BEF alongside leaders from @abbvie.bsky.social, Covington & Burling LLP, GSK, Merck, Novartis and @sobibird.bsky.social
September 11, 2025 at 4:23 PM
Proud to have our CBO Sarah Holland chair the Pharma Strategy & Dealmaking Panel at the #Sachs_BEF alongside leaders from @abbvie.bsky.social, Covington & Burling LLP, GSK, Merck, Novartis and @sobibird.bsky.social
Aug 25–29: Our CBO Sarah Holland joins Biotechgate Digital Partnering to discuss partnering our T cell engagers for solid tumors & autoimmune diseases, and how our M-gager® platform is advancing a highly specific clinical pipeline.
Still spots open—reach out to connect!
Still spots open—reach out to connect!
August 13, 2025 at 2:57 PM
Aug 25–29: Our CBO Sarah Holland joins Biotechgate Digital Partnering to discuss partnering our T cell engagers for solid tumors & autoimmune diseases, and how our M-gager® platform is advancing a highly specific clinical pipeline.
Still spots open—reach out to connect!
Still spots open—reach out to connect!
Meet Romina Doerig, Developability Expert at CDR-Life.
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.
Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.
Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!
August 4, 2025 at 11:49 AM
Meet Romina Doerig, Developability Expert at CDR-Life.
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.
Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!
She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic.
Her motto: take the chance—you’ll regret the ones you don’t.
Fun fact: she never visits the same place twice!
CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer.
Built on our M-gager® platform. IND-enabling studies planned for H2 2025.
Details: bit.ly/46dO0ne
Built on our M-gager® platform. IND-enabling studies planned for H2 2025.
Details: bit.ly/46dO0ne
June 26, 2025 at 12:17 PM
CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer.
Built on our M-gager® platform. IND-enabling studies planned for H2 2025.
Details: bit.ly/46dO0ne
Built on our M-gager® platform. IND-enabling studies planned for H2 2025.
Details: bit.ly/46dO0ne
CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview:
pharmaboardroom.com/interviews/c...
pharmaboardroom.com/interviews/c...
June 3, 2025 at 12:13 PM
CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview:
pharmaboardroom.com/interviews/c...
pharmaboardroom.com/interviews/c...
Our CEO Christian Leisner will be at the Jefferies Global Healthcare Conference in NYC next week, sharing how our M-gager® platform is redefining T cell engager precision in solid tumors & autoimmune disease. Connect to learn more. #JefferiesHealthcare
May 29, 2025 at 11:32 AM
Our CEO Christian Leisner will be at the Jefferies Global Healthcare Conference in NYC next week, sharing how our M-gager® platform is redefining T cell engager precision in solid tumors & autoimmune disease. Connect to learn more. #JefferiesHealthcare
CDR-Life CBO Sarah Holland will be at #BIO2025 in Boston, June 16–19. Learn about our M-gager® platform + T cell engager therapies for cancer & autoimmune disease. Want to meet? Drop us a note.
May 28, 2025 at 7:30 PM
CDR-Life CBO Sarah Holland will be at #BIO2025 in Boston, June 16–19. Learn about our M-gager® platform + T cell engager therapies for cancer & autoimmune disease. Want to meet? Drop us a note.
We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf
May 28, 2025 at 12:26 PM
We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf
A big first for CDR-Life! Our team took on the legendary Sola Stafette relay in Zurich with incredible spirit — on the course and cheering from the sidelines. Still buzzing from the energy, teamwork & fun. Here’s to many more finish lines!
#TeamCDRLife #SolaStafette
#TeamCDRLife #SolaStafette
May 23, 2025 at 3:54 PM
A big first for CDR-Life! Our team took on the legendary Sola Stafette relay in Zurich with incredible spirit — on the course and cheering from the sidelines. Still buzzing from the energy, teamwork & fun. Here’s to many more finish lines!
#TeamCDRLife #SolaStafette
#TeamCDRLife #SolaStafette
#AACR2025 recap:
•CDR404 (MAGE-A4): Strong activity in "cold" tumors, less T-cell exhaustion, early signs of anti-tumor effect in Ph1
•CDR505 (KK-LC-1): 1st TCE for KK-LC-1+ tumors in HLA-A*01:01 pts—potent, precise, promising
Posters: www.cdr-life.com/our-science/...
•CDR404 (MAGE-A4): Strong activity in "cold" tumors, less T-cell exhaustion, early signs of anti-tumor effect in Ph1
•CDR505 (KK-LC-1): 1st TCE for KK-LC-1+ tumors in HLA-A*01:01 pts—potent, precise, promising
Posters: www.cdr-life.com/our-science/...
May 21, 2025 at 7:31 PM
#AACR2025 recap:
•CDR404 (MAGE-A4): Strong activity in "cold" tumors, less T-cell exhaustion, early signs of anti-tumor effect in Ph1
•CDR505 (KK-LC-1): 1st TCE for KK-LC-1+ tumors in HLA-A*01:01 pts—potent, precise, promising
Posters: www.cdr-life.com/our-science/...
•CDR404 (MAGE-A4): Strong activity in "cold" tumors, less T-cell exhaustion, early signs of anti-tumor effect in Ph1
•CDR505 (KK-LC-1): 1st TCE for KK-LC-1+ tumors in HLA-A*01:01 pts—potent, precise, promising
Posters: www.cdr-life.com/our-science/...
On #ClinicalTrialsDay, we honor the patients, clinicians & researchers driving progress. Our Phase 1 trial of CDR404 — a bispecific T-cell engager targeting MAGE-A4+ tumors — is a key step in advancing precision immunotherapy. Thank you for making it possible.
May 20, 2025 at 11:26 AM
On #ClinicalTrialsDay, we honor the patients, clinicians & researchers driving progress. Our Phase 1 trial of CDR404 — a bispecific T-cell engager targeting MAGE-A4+ tumors — is a key step in advancing precision immunotherapy. Thank you for making it possible.
Chicago bound! The CDR-Life team is heading to #ASCO25 to discuss our M-gager® platform and lead program CDR404, now in Phase 1 for MAGE-A4+ tumors as well as CDR609, our first program targeting a highly cancer specific surface antigen widely expressed in common tumor types. Let’s connect!!
May 15, 2025 at 3:31 PM
Chicago bound! The CDR-Life team is heading to #ASCO25 to discuss our M-gager® platform and lead program CDR404, now in Phase 1 for MAGE-A4+ tumors as well as CDR609, our first program targeting a highly cancer specific surface antigen widely expressed in common tumor types. Let’s connect!!
CDR-Life is at #BIOEquityEurope! CEO Christian Leisner is sharing how our M-gager® T cell engagers are advancing solid tumor & autoimmune therapies. Meet in person or join virtual partnering next week to connect. #TCellEngagers
May 13, 2025 at 6:32 PM
CDR-Life is at #BIOEquityEurope! CEO Christian Leisner is sharing how our M-gager® T cell engagers are advancing solid tumor & autoimmune therapies. Meet in person or join virtual partnering next week to connect. #TCellEngagers
Join CDR-Life at Swiss Biotech Day (May 5–6)! Hear from our VP Clare Price, and meet CEO Christian Leisner, and CBO Sarah Holland, as they showcase how M-gager® is transforming T cell engager therapy. Let’s connect! #SwissBiotechDay #immunotherapy
April 30, 2025 at 1:23 PM
Join CDR-Life at Swiss Biotech Day (May 5–6)! Hear from our VP Clare Price, and meet CEO Christian Leisner, and CBO Sarah Holland, as they showcase how M-gager® is transforming T cell engager therapy. Let’s connect! #SwissBiotechDay #immunotherapy
#InternationalWomensDay! At CDR-Life, we’re inspiring the next generation of scientists. Our team visited Neue Schule Zürich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!
March 7, 2025 at 11:58 AM
#InternationalWomensDay! At CDR-Life, we’re inspiring the next generation of scientists. Our team visited Neue Schule Zürich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!